Our 3D-TGP platform based method cultures chondrocytes with qualities suitable for ACI and MACI; One such criteria is lower SA-B-Gal expression, confirming youthful tissue suitable for transplant in improving clinical outcome of cell therapies to address cartilage damage.
Manuscript published in Stem Cell Reviews and Reports
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
Neu REFIX beta glucans improving Multiple Sclerosis patients’ gut microbiome awarded as the best poster
Nichi BRITE Beta glucans yileding clinically encouraging outcome in a trial was presented in the webinar that commemorated World Parkinsons Day held on the 10th April 2023
Neurology Live, a clinical neurologists focused media portal has published GN Corporation’s presentation at the MDA on the Clinical trial results of Neu REFIX in Duchenne Muscular Dystrophy
GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its
